Anticoagulation in the young

Heart

Volumn 90, Issue 7, 2004, Pages 808-812

  Monagle, Paul ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; REVIPARIN; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTERY THROMBOSIS; BLEEDING; BONE DEMINERALIZATION; CLINICAL TRIAL; CONGENITAL HEART DISEASE; DIET; DISEASE SEVERITY; DRUG APPROVAL; DRUG BINDING; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG INDICATION; DRUG LABELING; DRUG MEGADOSE; DRUG SOLUBILITY; HAIR LOSS; HEMOSTASIS; HUMAN; IN VITRO STUDY; INFANT DISEASE; INTRACARDIAC THROMBOSIS; LABORATORY TEST; NONHUMAN; OSTEOPOROSIS; PARTIAL THROMBOPLASTIN TIME; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; THROMBIN TIME; THROMBOEMBOLISM; TRACHEA DISEASE; TREATMENT INDICATION; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 3042539615     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2003.024299     Document Type: Review

References (40)

1. Monagle P. Thrombosis in paediatric cardiac patients. Sem Thromb Haemostas (in press.)
2. Nowak-Gottl U, Von Kries R, Gobel U. Neonatal symptomatic thromboembolism in Germany: two year survey. Arch Dis Child Fetal Neonatal Ed 1997;76:F163-7.
3. Schmidt B, Andrew M. Neonatal thrombosis: report of a prospective Canadian and international registry. Pediatrics 1995;96:939-43.
4. Andrew M, David M, Adams M, et al. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood 1994;83:1251-7. This paper was the first systematic report of venous thrombosis in children, which defined many of the current concepts of the epidemiology of venous thrombosis in children.
5. Monagle P, Adams M, Mahoney M, et al. Outcome of pediatric thromboembolic disease: a report from the Canadian childhood thrombophilia registry. Pediatr Res 2000;47:763-6.
6. Massicotte MP, Dix D, Monagle P, et al. Central venous catheter related thrombosis in children: analysis of the Canadian registry of venous thromboembolic complications. J Pediatr 1998;133:770-6.
7. van Ommen C, Heijboer H, Buller HR, et al. Venous thromboembolism in childhood: a prospective two year registry in the Netherlands. J Pediatr 2001;139:676-71.
8. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the full-term infant. Blood 1987;70:165-72.
9. Andrew M, Paes B, Johnston M. Development of the hemostatic system in the neonate and young infant. Am J Pediatr Hematol Oncol 1990;12:95-104.
10. Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the healthy premature infant. Blood 1988;72:1651-7.
11. Reverdiau-Moalic P, Delahousse B, Body G, et al. Evolution of blood coagulation activators and inhibitors in the healthy human fetus. Blood 1996;88:900-6.
12. Andrew M, Vegh P, Johnston M, et al. Maturation of the hemostatic system during childhood. Blood 1992;80:1998-2005. The seminal papers by Andrew and colleagues in the late 1980s to early 1990s defined the concept of developmental haemostasis. However, while the concept and trends have been proven by subsequent studies, the values reported in these papers cannot be extrapolated to laboratories using different analyser and reagent systems. Each laboratory must develop their own age related reference ranges.
13. Greffe BS, Marlar RA, Manco-Johnson MJ. Neonatal protein C: molecular composition and distribution in normal term infants. Thromb Res 1989;56:91-8.
14. Manco-Johnson MJ, Spedale S, Peters M, et al. Identification of a unique form of protein C in the ovine fetus: developmentally linked transition to the adult form. Pediatr Res 1995;37:365-72.
15. Nitschmann E, Berry L, Bridge S, et al. Morphological and biochemical features affecting the antithrombotic properties of the aorta in adult rabbits and rabbit pups. Thromb Haemost 1998;79:1034-40.
16. Andrew M, Schmidt B, Mitchell L, et al. Thrombin generation in newborn plasma is critically dependent on the concentration of prothrombin. Thromb Haemost 1990;63:27-30.
17. Andrew M, Mitchell L, Vegh P, et al. Thrombin regulation in children differs from adults in the absence and presence of heparin. Thromb Haemost 1994;72:836-42.
18. Chan AK, Berry L, Monagle P, et al. Decreased concentrations of heparinoids are required to inhibit thrombin generation in plasma from newborns and children compared to plasma from adults due to reduced thrombin potential. Thromb Haem 2002;87:606-13.
19. Massicotte P, Leaker M, Marzinotto V, et al. Enhanced thrombin regulation during warfarin therapy in children compared to adults. Thromb Haemost 1998;80:570-4.
20. Moalic P, Gruel Y, Body G, et al. Levels and plasma distribution of free and C4b-BP-bound protein S in human fetuses and full-term newborns. Thromb Res 1988;49:471-80.
21. Schwarz HP, Muntean W, Watzke H, et al. Low total protein S artigen but high protein S activity due to decreased C4b-binding protein in neonates. Blood 1988;71:562-5.
22. Nako Y, Ohki Y, Harigaya A, et al. Plasma thrombomodulin level in very low birthweight infants at birth. Acta Paediatr 1997;86:1105-9.
23. Van Dreden P, Auvrignon A, Leverger G, et al. Tissue factor pathway inhibitor in infants and children [abstract]. Thromb Haemostas 2001;85(suppl):P2134.
24. Vieira A, Berry L, Ofosu F, et al. Heparin sensitivity and resistance in the neonate: an explanation. Thromb Res 1991;63:85-98.
25. Andrew M, Schmidt B. The use of heparin in newborn infants. Semin Thromb Haemostas 1988;14:28-32.
26. Andrew M, Ofosu F, Schmidt B, et al. Heparin clearance and ex vivo recovery in newborn piglets and adult pigs. Thromb Res 1988;52:517-27.
27. Andrew M, Marzinotto V, Massicotte P, et al. Heparin therapy in pediatric patients: a prospective cohort study. Pediatr Res 1994;35:78-83.
28. Massicotte P, Adams M, Marzinotto V, et al. Low-molecular-weight heparin in pediatric patients with thrombotic disease: a dose finding study. J Pediatr 1996;128:313-18.
29. Massicotte MP, Adams M, Leaker M, et al. A nomogram to establish therapeutic levels of the low molecular weight heparin (LMWH), clivarine in children requiring treatment for venous thromboembolism (VTE) [abstract]. Thromb Haemostas 1997;78(suppl):282.
30. Kuhle S, Massicotte MP, Andrew M, et al. A dose-finding study of tinzaparin in pediatric patients [abstract]. Blood 2002;100:279a.
31. Dix D, Andrew M, Marzinotto V, et al. The use of low molecular weight heparin in pediatric patients: a prospective cohort study. J Pediatr 2000;136:439-45.
32. Streif W, Andrew M, Marzinotto V, et al. Analysis of warfarin therapy in pediatric patients: a prospective cohort study or 319 patients. Blood 1999;94:3007-14. The largest published cohort of children receiving warfarin treatment.
33. Haroon Y, Shearer MJ, Rahim S, et al. The content of phylloquinone (vitamin K1) in human milk, cows' milk and infant formula foods determined by high-performance liquid chromatography. J Nutr 1982;112:1105-17.
34. Michelson A, Bovill E, Andrew M. Antithrombotic therapy in children. Chest 1995;108(suppl 4):506-22S.
35. Monagle P, Michelson AD, Bovill E, et al. Antithrombotic therapy in children. Chest 2001;119:344S-70S. Evidence based approach to antithrombotic therapeutic guidelines specific for children. The next edition which is updated significantly is in press and will be published in 2004.
36. Massicotte P, for the REVIVE Study group, et al. An open label randomized controlled trial of low molecular weight heparin compared to heparin and vitamin K antagonists for the treatment of venous thromboembolic events in children: the REVIVE trial. Thromb Res 2003;109:85-92. One of the only published randomised controlled trials of antithrombotic treatment in children.
37. Severin T, Sutor AH. Heparin-induced thrombocytopenia in pediatrics. Semin Thromb Hemost 2001;27:293-9.
38. Smugge M. Heparin induced thrombocytopenia in children [abstract]. Pediatrics 2002;10:e10.
39. Massicotte P, Julian J, Webber C, et al. Osteoporosis: a potential complication of long term warfarin therapy [abstract]. Thromb Haemostas 1999;(suppl):1333a.
40. Monagle P, Newall F, Wong P, et al, eds. A cross-sectional survey of bone densitometry in children on long-term warfarin therapy. Blood 2002;100:281(a).